Pacific Biosciences of California, Inc. (PACB) stock
PACBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
$1.96−0.01 (-0.51%)
Close on Nov 13, 2026Market cap $609.23MP/E –Yield 0.00%
Pacific Biosciences of California operating margin
Operating margin is operating income as a percentage of revenue.
Pacific Biosciences of California's operating margin for the twelve months ending Sep 30, 2026 was -81.3%. For fiscal 2025 it was -346.2%, against -308.0% the year before. The highest annual figure on record is -31.4% in fiscal 2015.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -346.2% | −38.2 |
| FY2024 | Dec 31, 2024 | -308.0% | −141.2 |
| FY2023 | Dec 31, 2023 | -166.8% | +72.6 |
| FY2022 | Dec 31, 2022 | -239.4% | −78.2 |
| FY2021 | Dec 31, 2021 | -161.2% | −28.9 |
| FY2020 | Dec 31, 2020 | -132.3% | −21.7 |
| FY2019 | Dec 31, 2019 | -110.6% | +17.8 |
| FY2018 | Dec 31, 2018 | -128.4% | −32.4 |
| FY2017 | Dec 31, 2017 | -96.1% | −17.5 |
| FY2016 | Dec 31, 2016 | -78.5% | −47.1 |
| FY2015 | Dec 31, 2015 | -31.4% | +72.3 |
| FY2014 | Dec 31, 2014 | -103.7% | +171.4 |
| FY2013 | Dec 31, 2013 | -275.2% | +87.9 |
| FY2012 | Dec 31, 2012 | -363.1% | −39.0 |
| FY2011 | Dec 31, 2011 | -324.1% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -91.2% | +9.9 |
| Q2 FY2026 | Jun 30, 2026 | -114.4% | −1.6 |
| Q1 FY2026 | Mar 31, 2026 | -22.5% | +1132.0 |
| Q4 FY2025 | Dec 31, 2025 | -92.3% | +297.9 |
| Q3 FY2025 | Sep 30, 2025 | -101.1% | +59.2 |
| Q2 FY2025 | Jun 30, 2025 | -112.8% | +375.5 |
| Q1 FY2025 | Mar 31, 2025 | -1154.5% | −944.9 |
| Q4 FY2024 | Dec 31, 2024 | -390.1% | −240.1 |
| Q3 FY2024 | Sep 30, 2024 | -160.3% | −12.2 |
| Q2 FY2024 | Jun 30, 2024 | -488.3% | −334.5 |
| Q1 FY2024 | Mar 31, 2024 | -209.6% | +24.9 |
| Q4 FY2023 | Dec 31, 2023 | -150.0% | +168.3 |
| Q3 FY2023 | Sep 30, 2023 | -148.1% | +82.8 |
| Q2 FY2023 | Jun 30, 2023 | -153.8% | +37.8 |
| Q1 FY2023 | Mar 31, 2023 | -234.6% | −0.9 |
| Q4 FY2022 | Dec 31, 2022 | -318.4% | −138.8 |
| Q3 FY2022 | Sep 30, 2022 | -230.9% | −17.5 |
| Q2 FY2022 | Jun 30, 2022 | -191.6% | −68.9 |
| Q1 FY2022 | Mar 31, 2022 | -233.7% | −117.4 |
| Q4 FY2021 | Dec 31, 2021 | -179.6% | −91.2 |
| Q3 FY2021 | Sep 30, 2021 | -213.5% | −86.8 |
| Q2 FY2021 | Jun 30, 2021 | -122.7% | +0.5 |
| Q1 FY2021 | Mar 31, 2021 | -116.3% | +93.4 |
| Q4 FY2020 | Dec 31, 2020 | -88.4% | −24.2 |
| Q3 FY2020 | Sep 30, 2020 | -126.7% | +1.6 |
| Q2 FY2020 | Jun 30, 2020 | -123.3% | −24.3 |
| Q1 FY2020 | Mar 31, 2020 | -209.7% | −26.2 |
| Q4 FY2019 | Dec 31, 2019 | -64.1% | +92.7 |
| Q3 FY2019 | Sep 30, 2019 | -128.3% | +7.6 |
| Q2 FY2019 | Jun 30, 2019 | -99.0% | +1.8 |
| Q1 FY2019 | Mar 31, 2019 | -183.5% | −59.8 |
| Q4 FY2018 | Dec 31, 2018 | -156.8% | −74.5 |
| Q3 FY2018 | Sep 30, 2018 | -135.8% | −44.2 |
| Q2 FY2018 | Jun 30, 2018 | -100.8% | +20.7 |
| Q1 FY2018 | Mar 31, 2018 | -123.7% | −30.2 |
| Q4 FY2017 | Dec 31, 2017 | -82.3% | −12.8 |
| Q3 FY2017 | Sep 30, 2017 | -91.6% | – |
| Q2 FY2017 | Jun 30, 2017 | -121.5% | – |
| Q1 FY2017 | Mar 31, 2017 | -93.5% | – |
| Q4 FY2016 | Dec 31, 2016 | -69.5% | – |
See a number that looks wrong?